Abstract 38P
Background
CD47 and SIRPα (signal-regulatory protein) are tumor biomarkers of innate immunity, expressed on cancer cells and tumor associated macrophages (TAMs); their interaction provides a “don’t eat me” signal that impairs phagocytosis. The relationship between CD47/SIRPα expression and BC aggressiveness has been investigated, however, its prognostic role is not clarified. With these premises, we have assessed the distribution and the possible prognostic value of CD47/SIRPα expression in early BC.
Methods
To verify our hypothesis, we first used in silico data from GOBO and GEPIA, two publicly available datasets: GOBO is a public repository containing microarray data (Affymetrix U133A) from 1881 early BC patients, with a median follow up of 120 months. GEPIA is a web server for analysing RNA expression data of tumours and normal samples from the TCGA and the GTEx projects, by a standard processing pipeline. Immunohistochemical (IHC) analyses were retrospectively performed on formalin-fixed paraffin embedded tissue (FFPE) samples in a cohort of 105 BC patients referred to our institution. The association between CD47 and SIRPα expression levels and outcome was evaluated using the χ2 test. Disease free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier life table method.
Results
In silico data showed that CD47 and SIRPα are preferentially expressed in triple negative (TN) BC, as compared to other BC subtypes (p< 0.0001). CD47 upregulation is associated to a worse OS only in Luminal A BC (GOBO p<0.001, n= 189 patients). By IHC analysis in our retrospective series, CD47 was overexpressed in 80% of TNBC and in 56% of Luminal BC samples. Of note, SIRPα was expressed in 20% of TAMs and in 50% of TN BC samples.
Conclusions
Biomarkers of innate immunity are represented but differently expressed in the different BC subtypes; IHC analyses are ongoing to consolidate this result and to assess their prognostic role in our patient cohort. Final analyses will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session